PMID- 15714958
OWN - NLM
STAT- MEDLINE
DCOM- 20050302
LR  - 20161124
IS  - 0301-2603 (Print)
IS  - 0301-2603 (Linking)
VI  - 33
IP  - 2
DP  - 2005 Feb
TI  - [Intra-arterial administration of fasudil hydrochloride: duration of action].
PG  - 133-40
AB  - Intra-arterial infusion (IA) of fasudil hydrochloride for cerebral vasospasm is 
      performed in many institutions and is associated with few side effects. 
      Nonetheless, as optimum dose and duration of action remain unknown, the present 
      study aimed to clarify these variables. We performed intra-arterial injection of 
      fasudil hydrochloride for eight patients with cerebral vasospasm 7-13 days after 
      subarachnoid hemorrhage. Fasudil hydrochloride was administered via the internal 
      carotid artery without selective microcatheterization, at a concentration and 
      speed of 30 mg/20 ml/10-15 min, using a total dose of 30-60 mg. Cerebral 
      angiography was used to measure change in blood vessel diameter at 19 points, and 
      perfusion CT was used to detect changes in cerebral blood perfusion (CBP), 
      cerebral blood volume (CBV), and mean transit time (MTT) at 12 hemispheres. 
      Investigations were performed before IA, immediately after IA (post IA), and 4.5 
      to 6 hours later. For central vessels, (A1, M1) mean change in diameter (cm) 
      measured pre IA, post IA, and 4.5-6 hours later was 1.2 +/- 0.68, 1.5 +/- 0.72, 
      and 1.2 +/- 0.7, respectively. For peripheral vessels (peripheral to A1, M1, and 
      the ophthalmic artery) change in diameter (cm) was 0.65 +/- 0.16, 0.97 +/- 0.24, 
      and 0.71 +/- 0.24, respectively. Average CBP (m/100g/min) in the infused 
      hemisphere at pre IA, post IA, and 4.5-6 hours later was 41.6 +/- 3.56, 46.4 +/- 
      5.82, 41.6 +/- 7.42, respectively. Average CBV (ml/100g) was 2.72 +/- 0.21, 2.73 
      +/- 0.21, 2.91 +/- 0.42, respectively and average MTT (sec) was 5.16 +/- 0.38, 
      4.57 +/- 0.70, 5.55 +/- 1.0, respectively. Changes in peripheral vessel diameter 
      and in MTT were statistically significant. Therefore, when performing 
      intra-arterial administration of fasudil hydrochloride, clinicians should be 
      aware that vasodilator effect is less than 6 hours.
FAU - Ono, Kenichiro
AU  - Ono K
AD  - Department of Neurosurgery, Japan Self Defense Forces Central Hospital, Tokyo.
FAU - Shirotani, Toshiki
AU  - Shirotani T
FAU - Wada, Kojiro
AU  - Wada K
FAU - Takahara, Takashi
AU  - Takahara T
FAU - Matsushita, Yoshitaro
AU  - Matsushita Y
FAU - Yuba, Koji
AU  - Yuba K
FAU - Yamana, Daigo
AU  - Yamana D
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - No Shinkei Geka
JT  - No shinkei geka. Neurological surgery
JID - 0377015
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Vasodilator Agents)
RN  - 84477-87-2 (1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine)
RN  - Q0CH43PGXS (fasudil)
SB  - IM
MH  - 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/*administration & dosage/*analogs & 
      derivatives/*pharmacology
MH  - Aged
MH  - Carotid Artery, Internal
MH  - Cerebral Arteries/pathology
MH  - Cerebrovascular Circulation
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Injections, Intra-Arterial
MH  - Male
MH  - Middle Aged
MH  - Subarachnoid Hemorrhage/complications
MH  - Vasodilator Agents/*administration & dosage/*pharmacology
MH  - Vasospasm, Intracranial/*drug therapy/physiopathology
EDAT- 2005/02/18 09:00
MHDA- 2005/03/03 09:00
CRDT- 2005/02/18 09:00
PHST- 2005/02/18 09:00 [pubmed]
PHST- 2005/03/03 09:00 [medline]
PHST- 2005/02/18 09:00 [entrez]
PST - ppublish
SO  - No Shinkei Geka. 2005 Feb;33(2):133-40.